Veverimer for Osteopenia

This trial tests a treatment called veverimer, a potential new drug, to determine if it can reduce bone loss in individuals with osteopenia, a condition where bones are weaker than normal. Researchers aim to discover if veverimer lowers acid levels in urine, potentially slowing bone resorption (the breakdown of bone tissue). The trial will also assess veverimer's safety and its effects on bone health and physical performance. Participants should have osteopenia and follow a diet high in acid but should not have conditions like asthma or diabetes requiring insulin. As a Phase 1 trial, this research focuses on understanding how veverimer works in people, offering participants the opportunity to be among the first to receive this new treatment.

You won't have to stop taking your current medications, but you must agree not to change your medication use during the study.

Research has shown that veverimer is generally well-tolerated. In earlier studies, only a small number of patients experienced serious side effects. Specifically, about 2% of those taking veverimer had serious issues, compared to 5% in the placebo group. Common side effects included headaches, diarrhea, and gas, similar to those in people not taking the drug. Studies found no interactions with other medications, suggesting veverimer is quite safe to use. However, as with any treatment, individual experiences may vary.¹²³⁴⁵

Most treatments for osteopenia focus on increasing bone density through medications like bisphosphonates or hormone therapies. Veverimer is unique because it operates differently, targeting the body's acid-base balance. Researchers are excited about Veverimer because it has a novel mechanism of action that might improve bone health by reducing metabolic acidosis, which is a less explored pathway in osteopenia treatment. This approach could offer a new avenue for people who don't respond well to existing medications or who experience side effects.

Research has shown that veverimer may help treat issues related to metabolic acidosis. In earlier studies, veverimer successfully raised bicarbonate levels in the blood, indicating a better acid balance in the body. This is important because a healthier acid balance might help reduce bone loss. Patients with chronic kidney disease who used veverimer reported better physical function, suggesting it could improve overall health. Although direct evidence on veverimer for osteopenia is limited, its ability to lower acid levels makes it a possible option for reducing bone loss in this condition. Participants in this trial will receive either veverimer 9 g/day, veverimer 9 g/every other day, or a placebo to evaluate its effects on osteopenia.¹²⁶⁷⁸